Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now?

NodeGuardian

2026-03-16 11:54:19

Abstract generation in progress

This article analyzes ImmunityBio, Inc. (IBRX) as a potential bullish stock, highlighting its unusual combination of extreme short interest (40% of float), accelerating fundamentals with 424% year-over-year revenue growth, and rapid clinical and regulatory catalysts. The chairman’s indication of multiple upcoming press releases and recent positive developments in NSCLC and Saudi FDA approval contribute to the bullish outlook. The piece suggests a potential short squeeze if the stock rises above $3.00, driven by the confluence of strong catalysts, strengthening revenue, and structural short pressure.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.